Study S002308

Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan: Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05577728
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 2316
Start: 2021-07-01
Primary completion: 2022-10-31
Lead sponsor: Brigham and Women's Hospital
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:New use of semaglutide injection; DRUG:New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
Results posted: FALSE

Registered primary outcomes

Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol) [At year 1]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016524	Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care. Kattinakere Sreedhara S, BMJ open diabetes research & care	2025	Randomized trial	PMID 41161770 DOI	cites ClinicalTrials.gov:NCT05577728; registry reference DERIVED:41161770